ACCEPTED. Instrument in Female Self-obtained Vaginal Swabs and Male Urine Samples. Andrew Hardick 1. Justin Hardick 1.

Similar documents
NIH Public Access Author Manuscript Sex Transm Infect. Author manuscript; available in PMC 2013 June 04.

Evaluation of CDC-Recommended Approaches for Confirmatory Testing of Positive Neisseria gonorrhoeae Nucleic Acid Amplification Test Results

Comparison of Three Nucleic Acid Amplification Tests for Detection of Chlamydia trachomatis in Urine Specimens

1 VU University Medical Centre, Department of Medical Microbiology & Infection Control, Laboratory of

Use of Nucleic Acid Amplification Testing for the Diagnosis of Anorectal Sexually. Transmitted Infections. Lisa A. Cosentino 1,2.

Received 16 December 2005/Returned for modification 6 February 2006/Accepted 6 May 2006

Rapid Antigen Testing Compares Favorably with Transcription-Mediated Amplification Assay for the Detection of Trichomonas vaginalis in Young Women

OBJECTIVES. Emerging Laboratory Diagnostic Options for Sexually-transmitted Infections

Emerging Laboratory Diagnostic Options for Sexually-transmitted Infections

amplification assay and BD Affirm VPIII for detection of Trichomonas vaginalis in

7/24/2012. Estimates of Sexually Transmitted Infections in the U.S.

Performance of the Abbott RealTime CT/NG for Detection of

Effect of Endocervical Specimen Adequacy for Detection of ACCEPTED. Wyoming Public Health Laboratory, 517 Hathaway Bldg., 2300 Capitol Ave.

Performance of the Abbott RealTime CT/NG for the Detection of Chlamydia. trachomatis and Neisseria gonorrhoeae

Prevalence of Trichomonas vaginalis by PCR in Men Attending a Primary Care Urology Clinic in South Korea

APTIMA Combo 2 Testing Detected Additional Cases of Neisseria. gonorrhoeae in Men and Women in Community Settings. * Corresponding Author at:

Methods for Detection of Trichomonas vaginalis in the Male Partners of Infected Women: Implications for Control of Trichomoniasis

Industry Sponsored Symposia. Québec City, CANADA JULY 10 TO 13,

Evaluation of Nucleic Acid Amplification Tests as Reference Tests for Chlamydia trachomatis Infections in Asymptomatic Men

OTHER BODY SITES PATHOGENIC FLAGELLATE

LABORATORY VALIDATION OF XPERT CT/NG AND TV TESTING AS PERFORMED BY NURSES AT THREE PRIMARY HEALTHCARE FACILITIES IN SOUTH AFRICA

Duration of Persistence of Gonococcal DNA Detected by Ligase Chain Reaction in Men and Women following Recommended Therapy for Uncomplicated Gonorrhea

Received 22 July 2005/Returned for modification 15 September 2005/Accepted 24 November 2005

Real-time PCR improves detection of Trichomonas vaginalis infection compared with culture using self-collected vaginal swabs

Outline. Trichomoniasis: Testing and Treatment Update. What s in a name? From the Greek: trichos, hair monas, unit, single

Controls for Chlamydia trachomatis and Neisseria gonorrhoea

Control Efforts for Trichomoniasis in STD Clinics

Controls for Chlamydia trachomatis and Neisseria gonorrhoea

Clinical Evaluation of the Cepheid Xpert TV Assay for Detection of Trichomonas Vaginalis with Prospectively Collected Female and Male Specimens.

Received 8 September 2005/Returned for modification 12 October 2005/Accepted 9 November 2005

Correct samples for diagnostic tests in sexually transmitted diseases: which sample for which test? 1

Evaluation of the Digene Hybrid Capture II Assay with the Rapid Capture System for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae

Mycoplasma genitalium:

Received 11 April 2003/Returned for modification 10 June 2003/Accepted 30 June 2003

Received 26 November 2003/Returned for modification 6 January 2004/Accepted 6 April 2004

Diagnostic Rates Vary Based Upon the Number of Read Days Using the

Buve, A., H. A. Weiss, et al. (2001). The epidemiology of trichomoniasis in women in four African cities. Aids 15 Suppl 4: S89-96.

The Prevalence of Trichomonas vaginalis Infection among Reproductive-Age Women in the United States,

Received 26 November 2008/Returned for modification 4 February 2009/Accepted 2 April 2009

SOME ETIOLOGIES OF STI OBJECTIVES CHLAMYDIA TRENDING. Things are Heating Up: An Update on Emerging Sexually-transmitted Infection Agents

Received 12 March 2007/Returned for modification 20 June 2007/Accepted 27 September 2007

UPDATE MOLECULAR DIAGNOSTICS IN SEXUAL HEALTH. Dr Arlo Upton Clinical Microbiologist Labtests Auckland

Index. Infect Dis Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.

Received 5 March 2007/Returned for modification 17 May 2007/Accepted 11 June 2007

4. RED AND BLUE TOP COLLECTION SWABS WILL NO LONGER BE SUPPLIED FOR BACTERIAL CULTURE

Unprotected sex in an STD clinic population: Agreement between self-reported condom use and PCR detection of y-chromosome in vaginal fluid

Assessment of co-infection of Sexually Transmitted pathogen microbes by

2014 CDC GUIDELINES CHLAMYDIA & GONORRHEA DIAGNOSTICS. Barbara Van Der Pol, PhD, MPH University of Alabama at Birmingham

Received 20 September 2006/Returned for modification 30 October 2006/Accepted 20 December 2006

Prevalence of Trichomonas vaginalis and Coinfection with Chlamydia trachomatis and

Trichomonas vaginalis Genital Infections: Progress and Challenges

PERFORMANCE OF THE COBAS CT/NG TEST COMPARED TO THE APTIMA AC2

Trichomonas Time to Know the Facts

Performance of Chlamydia trachomatis and Neisseria gonorrhoeae nucleic acid amplification assays using low level controls

Evaluation of the Abbott RealTime CT/NG Assay in Comparison to the Roche Cobas Amplicor CT/NG Assay

Technical Bulletin No. 98b

/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.

Professor Jonathan Ross

Complex Vaginitis Cases: Applying New Diagnostic Methods to Enhance Patient Outcomes ReachMD Page 1 of 5

Amplification-based Analyte-specific Reagent Testing in a ACCEPTED. Metropolitan Setting of High Sexually-transmitted Disease Prevalence

Chlamydia trachomatis and Neisseria gonorrhoeae are the two most commonly. crossm

Received 25 March 2008/Returned for modification 13 June 2008/Accepted 19 August 2008

**Florida licensees, please note: This exercise is NOT intended to fulfill your state education requirement for molecular pathology.

New diagnostic tests for sexually transmitted infections. Jens Van Praet 30/11/2018

Reliable, cost-effective CT/GC testing For labs with low to medium throughput needs. The BD ProbeTec ET System

Clinical Performance of Roche COBAS 4800 HPV Test

Genital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management. William M. Geisler M.D., M.P.H. University of Alabama at Birmingham

Ackers, JP (2003) Trichomonas. In: The Oxford Textbook of Medicine. Oxford University Press, Oxford, 1:783-4.

New CT/GC Tests. CDC National Infertility Prevention Project Laboratory Update Region II May 13-14, 2009

NIH Public Access Author Manuscript Sex Transm Dis. Author manuscript; available in PMC 2009 July 16.

Masatoshi Tanaka, Hiroshi Nakayama, Kazuyuki Sagiyama, Masashi Haraoka, Hiroshi Yoshida, Toshikatsu Hagiwara, Kohei Akazawa, Seiji Naito

CHLAMYDIA/GC AMPLIFIED RNA ASSAY

DETECTION OF NEISSERIA GONORRHOEAE USING MOLECULAR METHODS

Trichomonas vaginalis Infection in Male Sexual Partners: Implications for Diagnosis, Treatment, and Prevention

Women by testing SurePath Liquid-Based Pap Specimens in APTIMA Assays ACCEPTED. Peter D Ascoli 5, Mark Martens 6

GeneXpert System. On-Demand Molecular Testing for the Physician Office Laboratory

FEDERAL PUBLIC SERVICE, HEALTH, FOOD CHAIN SECURITY AND ENVIRONMENT CLINICAL BIOLOGY COMMISSION CLINICAL BIOLOGY SECTION

Evaluation of Syndromic Algorithms for Managing Sexually Transmitted Infections Among Pregnant Women in Kenya

Introduction Material and methods Sample size 2 Kiranmai and Neelima

Answers to those burning questions -

A Comparison of Ligase Chain Reaction to

IMMUNOGLOBULIN LEVELS IN SERUM AND CERVICOVAGINAL SECRETIONS OF PATIENTS INFECTED WITH TRICHOMONAS VAGINALIS

Prevalence of Mycoplasma genitalium and Azithromycin-Resistant. Infections Among Remnant Clinical Specimens, Los Angeles ACCEPTED

Here s the Point! Rapid, Point-of-Care Testing for Sexually Transmitted Infections

6/11/15. BACTERIAL STDs IN A POST- HIV WORLD. Learning Objectives. How big a problem are STIs in the U.S.?

Received 12 July 2004/Returned for modification 29 August 2004/Accepted 18 October 2004

7/13/2018. NEW TESTS - Please update your EMR catalog with those appropriate to your practice

Home Screening for Bacterial Vaginosis to Prevent Sexually Transmitted Diseases

TECHNICAL PAPERS ON HEALTH AND BEHAVIOR MEASUREMENT

JOURNAL OF CLINICAL MICROBIOLOGY, July 1999, p Vol. 37, No. 7. Copyright 1999, American Society for Microbiology. All Rights Reserved.

ACCEPTED. Northwestern University Feinberg School of Medicine, Chicago, IL 5

Nucleic Acid Amplification Testing for the Diagnosis of TB

Received 21 March 2005/Returned for modification 25 April 2005/Accepted 9 June 2005

Her Diagnosis Matters: What Can You Do to Prevent Misdiagnosis of Vaginitis?

InPouch TV TM culture for detection of Trichomonas vaginalis

Enzyme immunoassay for urogenital trichomoniasis as a marker of unsafe sexual behaviour

Nucleic Acid Amplification Tests for Diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis Rectal Infections

Laboratory for Clinical and Biological Studies, University of Miami Miller School of Medicine, Miami, FL, USA.

Transcription:

JCM Accepts, published online ahead of print on 30 August 2006 J. Clin. Microbiol. doi:10.1128/jcm.01447-06 Copyright 2006, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. Comparison between the Gen-Probe TMA Trichomonas vaginalis Research Assay and a Real-time PCR for Trichomonas vaginalis using the Roche Lightcycler Instrument in Female Self-obtained Vaginal Swabs and Male Urine Samples Andrew Hardick 1 Justin Hardick 1 Billie Jo Wood 1 Charlotte Gaydos 1 1 Division of Infectious Diseases, Johns Hopkins University, School of Medicine, MD Corresponding author: Charlotte A. Gaydos, Dr.P.H. Associate Professor 1159 Ross Building 720 Rutland Ave. Baltimore, MD 21015 Phone: 410-614-0932 FAX: 410-614-9775 cgaydos@jhmi.edu Results from this analysis were presented in part at the International Society for Sexually Transmitted Diseases Research, Amsterdam, The Netherlands, July 10-13, 2005. Funding was in part from Gen-Probe, Inc., San Diego, CA.

Abstract This study compared two assays for Trichomonas vaginalis detection, Gen- Probe s TMA-TV and BTUB FRET PCR in self-obtained clinical samples from 611 patients. Infection status was defined as 2 positives by 2 different tests. Initial TMA-TV sensitivity was 96.7%; specificity was 97.5%. The TMA-TV assay was comparable to BTUB FRET PCR. Manuscript Trichomonas vaginalis (TV) is the most common parasitic sexually-transmitted infection in the world and is estimated to cause 3 million infections in the US annually year (1, 21). TV can cause vaginitis, cervicitis, preterm labor, urethritis and prostatitis (3,32,33). TV is cytopathic to vaginal cells and is associated with other STDs infections, including transmission of HIV (2, 7, 26, 29). Conventional methods for diagnosing TV are microscopic examination of wet mount preparations and culture-based systems. Both methods rely of the collection of viable organisms and suffer from poor sensitivity (25). More sensitive research-based PCRs for the diagnosis of TV have been described (9,11-16, 22, 24). Development of a commercially available amplification assay for TV on selfcollected samples would be highly desirable from a patient, clinical, and public health perspective (6). Other commercially available FDA cleared STD tests such as those for chlamydia and gonorrhea could be performed on the self-obtained samples (4,5,27,28). We report a comparison of a research transcription-mediated amplification assay for TV (TMA-TV), now available as an analyte specific reagent (ASR) (Gen-Probe Inc., San Diego, CA) with BTUB FRET PCR (BTUB), a real-time research PCR (9). 2

We screened 615 people attending two STD clinics; 611 had male urine samples (N=290) or duplicate female self-obtained vaginal swabs (SOVS) (N= 321) collected. Institutional Review Board approval was obtained, and the study was funded in part by Gen-Probe. BTUB PCR. For females, two SOVS for BTUB and TMA-TV testing were collected in random order. SOVS for BTUB testing were transported in a dry state and were rehydrated in 1 ml of Tris-EDTA buffer, of which 200 ul was used for DNA robotic extraction. Similarly 200ul of male urine was subjected to this automated DNA extraction (MagNA Pure LC instrument, Roche Diagnostics, Indianapolis, IN). The BTUB PCR assay design was based on FRET probe chemistry (Roche Diagnostics). Use of positive and negative controls, thermocycling protocol, data analysis, and specific sequences of primers and probes were previously published using the Roche LightCycler Instrument (9). TMA-TV. The SOVS were placed in Specimen Transport Media (Gen-Probe) and male urine was pipetted into Urine Specimen Transport Tubes for testing. The male urine and female SOVS were tested using target capture TMA and detection by the hybridization protection assay (HPA) in a manner similar to the other Gen-Probe APTIMA family of assays (Gen-Probe APTIMA COMBO 2 Package insert, IN0037-04 Rev A, Gen-Probe Incorporated, San Diego, CA). Primers, probes and target capture oligomers were designed for TV based on the 16S rrna gene target. The cut-off for positive reactions was set by the investigators at 60,000 relative light units. Samples that tested positive by both the BTUB and TMA-TV were considered true positives. Discordant samples were adjudicated by another research PCR with 3

another primer set, TVK3 and TVK4, utilizing gel electrophoresis for end-point analysis (14). Results for vaginal wet preparation for motile trichomonads obtained during the clinic visit for females were also recorded for samples; no culture for trichomonas was performed. Samples positive by two of the three amplified tests or by one amplified test and a positive wet preparation result were also considered to be true positives for final sensitivity and specificity analysis. Overall, 59 samples were positive by BTUB and TMA-TV; 535 were negative by both; 15 were TMA-TV positive and BTUB negative; and 2 were TMA-TV negative and BTUB positive. Initially, compared only to BTUB results, TMA-TV sensitivity, specificity, PPV and NPV were 96.7%, 97.3%, 79.7%, and 99.6%, respectively (Table 1). After further testing of the 15 TMA-TV positive/btub negative samples, 10 were resolved as true positives; of 2 TMA-TV negative/btub positive samples, 1 female resolved as a true positive. Final TMA-TV sensitivity was 98.6% (69/70) and specificity was 99.1% (536/541) (Table 1). For males, final sensitivity and specificity was 100%. All male TMA-TV positive/btub negative samples were TVK3/4 positive (Table 2). Final prevalence in males was 4.5%. For females, final sensitivity and specificity were 98.2% (56/57) and 98.1% (259/264), respectively (Table 3). Of the 12 female TMA-TV positive/btub negative samples, 7/12 were TVK3/4 positive, 2/12 were TVK3/4 negative, 2/12 were of quantity not sufficient (QNS) for TVK3/4 analysis. They were graded true negatives based on wet preparation negative results. The remaining discordant sample (1/12) was QNS for further resolution. It was considered negative based on wet preparation results 4

(Table 3). Overall prevalence in women was 17.8%. The prevalence by vaginal wet preparation in the clinic was 12.1%; sensitivity was 68.4% (39/57). Kappa statistic analysis for comparison between TMA-TV and BTUB indicated an overall kappa value of 0.858. For men, kappa value was 0.826, for women it was 0.858. Kappa analysis indicated almost perfect" agreement. There was a high prevalence of 11.5% of T. vaginalis in our study population. Females had a higher prevalence (17.8%) for TV in our population than men (4.5%). This data is similar to our STD clinic population and Miller at el. (18, 30,31). Male urine and SOVS have been shown to be acceptable for the detection of TV (9,10,16,20,23,31). In our study, these self-obtained samples demonstrated a very high initial sensitivity and specificity for TMA-TV of 96.7% and 97.3% respectively, and the TMA-TV assay had excellent resolved sensitivity and specificity at 98.6% and 99.1%. Kappa statistic analysis between the two assays indicated an almost perfect agreement. There were very few discordant samples, although the TMA-TV identified more positives, indicating that the TMA-TV may be more sensitive. Additional testing was not performed on all the samples due to economic constraints. We recognize this potentially introduced some bias into the results (8,17,19). Culture, the gold standard, is inherently limited because it relies on viable organism for detection. Wet preparation and culture are subject to interpretation by the microscopist, whereas nucleic acid amplification assays offer may offer more accurate and objective results (16, 30). The Gen-Probe TMA-TV assay is commercially available as an ASR (analyte specific reagent) and offers laboratories a highly sensitive and 5

specific assay for use clinically; hopefully it will become available as a fully FDA cleared test. Reference List 1. Centers for Disease Control and Prevention. 2005. Sexually transmitted disease surveillance, 2004. Atlanta, GA: U.S. Department of Health and Human Services, September 2005. CDC. 2. Cohen, M. S. 1998. Sexually transmitted diseases enhance HIV transmission: No longer a hypothesis. Lancet 351 (suppl III):5-7. 3. Cotch M.F., J.G. Pastorek, R.P. Nugent, S.L. Hillier, R.S. Gibbs, D.H. Martin, D.A. Eschenbach, R. Edelman, J.C. Carey, J.A. Regan, M.A. Krohn, M.A. Klebanoff, A.V. Rao, and G.G. Rhoads. 1997. Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex Transm Dis. 24: 353-60. 4. Gaydos C.A. 2005. Nucleic Acid Amplification Tests for Gonorrhea and Chlamydia: Practice and Applications, p. 367-386. In J. M. Zenilman and Jr. R. C. Moellering (eds.), Infect Dis Clin N Am. Elsevier Saunders, Philadelphia. 5. Gaydos, C. A., T. C. Quinn, D. Willis, A. Weissfeld, E. W. Hook, D. H. Martin, D. V. Ferrero, and J. Schachter. 2003. Performance of the APTIMA Combo 2 6

assay for the multiplex detection of Chlamydia trachomatis and Neisseria gonorrheae in female urine and endocervical swab specimens. J Clin Microbiol 41:304-309. 6. Gaydos, C. A. and Rompalo A.M. 2002. The use of urine and self-obtained vaginal swabs for the diagnosis of sexually transmitted diseases. Current Infect.Dis.Reports 4:148-157. 7. Gilbert, R., G. Elia, D. Beach, S. Klaessig, and B. Singh. 2000. Cytopathic effect of Trichomonas vaginalis on human vaginal epithelial cells cultured in vitro. Infect Immun 68:4200-4206. 8. Green, T. A., C. M. Black, and R. E. Johnson. 1998. Evaluation of bias in diagnostic test sensitivity and specificity estimates computed by discrepant analysis. J Clin Microbiol 36:375-381. 9. Hardick, J., S. Yang, L. Lin, D. Duncan, and C. A. Gaydos. 2003. Use of the Roche LightCycler Instrument in a Real-time PCR for Trichomonas vaginalis in urine samples from females and males. J.Clin.Microbiol 41:5619-5622. 10. Hsieh, Y.-H., M. R. Howell, J. C. Gaydos, J. K. T. McKee, T. C. Quinn, and C. A. Gaydos. 2003. Preference among female army recruits for use of selfadministered vaginal swabs or urine to screen for Chlamydia trachomatis genital infections. Sex. Transmit. Dis 30: 769-773, 2003. 7

11. Jordan, J. A., D. Lowery, and M. Trucco. 2001. TaqMan-based detection of Trichomonas vaginalis DNA from female genital specimens. J Clin Microbiol 39:3819-3822. 12. Kaydos-Daniels, S. C., W. C. Miller, I. Hoffman, T. Bnda, W. Dzinyemba, F. Martinson, M. S. Cohen, and M. M. Hobbs. 2003. Validation of a urine-based PCR-enzyme-linked immunosorbent assay for use in clinical research settings to detect Trichomonas vaginalis in men. J.Clin.Microbiol. 41:318-323. 13. Kaydos, S. C., H. Swygard, S. L. Wise, A. C. Sena, P. A. Leone, W. C. Miller, M. S. Cohen, and M. M. Hobbs. 2002. Development and validation of a PCRbased enzyme-linked immunosorbant assay with urine for use in clinical research settings to detect Trichomonas vaginalis in women. J.Clin.Micrbiol. 40:89-95. 14. Kegne, P., F. Veas, N. Vidal, J. L. Rey, and G. Cuny. 1994. Trichomanas vaginalis repeated DNA target for highly sensitive and specific polymerase chain reaction diagnosis. Cell and Molec Bio 40:819-831. 15. Lawing, L. F., J. R. Hedges, and J. R. Schwebke. 2000. Detection of trichomonosis in vaginal and urine specimens from women by culture and PCR. J Clin Microbiol 38:3585-3588. 8

16. Madico, G., T. C. Quinn, A. Rompalo, Jr. K. T. McKee, and C. A. Gaydos. 1998. Detection of Trichomonas vaginalis infection by polymerase chain reaction (PCR). J Clin Microbiol 36:3205-3210. 17. McAdam, A. J. 2000. Discrepant analysis: how can we test a test? J.Clin Microbiol 38 :2027-2029. 18. Miller, W. C., H. Swygard, M. M. Hobbs, C. A. Ford, M. S. Handcock, M. Morris, J. L. Schmitz, M. S. Cohen, Harris K.H., and J. R. Udry. 2005. The prevalence of trichomoniasis in young adults in the United States. Sex Tansmit Dis 32:593-598. 19. Miller, W. C. 1998. Bias in discrepant analysis: when two wrongs don't make a right. J Clin Epidemiol 51:219-231. 20. Newman, S. B., M. B. Nelson, C. A. Gaydos, and H. B. Friedman. 2003. Female prisoners' preference of collection methods for testing for Chlamydia trachomatis and Neisseria gonorrhoeae infection. Sex Trans Dis 30:306-309. 21. Petrin, D., K. Delgaty, R. Bhatt, and L. P. Garber. 1998. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev 11:300-317. 9

22. Riley, D., M. Roberts, T. Takayama, and J. N. Krieger. 1992. Development of a polymerase chain reaction-based diagnosis of Trichomonas vaginalis. J Clin Microbiol 30:465-472. 23. Rompalo, A. M., C. A. Gaydos, N. Shah, M. Tennant, K. A. Crotchfield, G. Madico, T. C. Quinn, R. Daniel, K. V. Shah, J. C. Gaydos, and J. K. T. McKee. 2001. Evaluation of use of a single intravaginal swab to detect multiple sexually transmitted infections in active-duty military women. Clin Inf Dis 33:1455-1461. 24. Schwebke, J.R., L.F. Lawing. 2002. Improved detection by DNA amplification of Trichomonas vaginalis in males. J. Clin. Microbiol. 40:3681-3683. 25. Soper, D. 2004. Trichomoniasis: Under control or undercontrolled? Amer J.Obstet.Gynecol 190:281-290. 26. Sorvillo, F., L. Smith, P. Kerndt, and L. Ash. 2001. Trichomonas vaginalis, HIV, and African-Americans. Emerg Infect Dis 7:927-932. 27. Van Der Pol, B., D. Ferrero, L. Buck-Barrington, E. Hook III, C. Lenderman, T. C. Quinn, Gaydos CA, J. Moncada, G. Hall, M. J. Tuohy, and B. R. Jones. 2001. Multicenter evaluation of the BDProbeTec ET system for the detection of Chalmydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical swabs, and male urethral swabs. J Clin Microbiol 39:1008-1016. 10

28. Van Der Pol, B., Quinn T.C., Gaydos CA, K. Crotchfelt, J. Schachte, J. Moncada, D. Jungkind, D. H. Martin, B. Turner, C. Peyton, and R. B. Jones. 2000. Evaluation of the AMPLICOR and Automated COBAS AMPLICOR CT/NG Tests for the Detection of Chlamydia trachomatis. J Clin Microbiol 38:1105-1112. 29. Wang, C. C., R. S. McClelland, and M. Reilly. 2001. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 183:1017-1022. 30. Wendel, K. A., E. J. Erbelding, C. A. Gaydos, and A. M. Rompalo. 2002. Trichomonas vaginalis polymerase chain reaction compared with standard diagnostic and therapeutic protocols for detection and treatment of vaginal trichomoniasis. Clin Infect Dis 35:576-580. 31. Wendel, K. E., E. J. Erbelding, C. A. Gaydos, and A. M. Rompalo. 2003. Use of urine polymerase chain reaction to define the prevalence and clinical presentation of Trichomonas vaginalis in men attending an STD clinic. Sex Transmit Inf 79:151-153. 32. Zhang, Z. F. and C. B. Begg. 1994. Is Trichomanas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. Int J of Epidem 23:682-690. 11

33. Zhang, Z. F., G. Saxon, Y. S. Zhang, J. Marshall, M. Zielezny, and Y. X. Chen. 1995. Trichomonas vaginalis and cervical cancer: A prospective study in China. Ann Epidemiol 5:325-332. 12

Table 1. Comparison of TMA-TV results to BTUB FRET PCR results for Trichomonas vaginalis from 611 patients; 321 women and 290 men. Data type PCR Sensitivity Specificity % PPV % NPV % Initial α TMA-TV 96.7% (59/61) 97.3% (535/550) 79.7% (59/74) 99.6% (535/537) Female Male 98.0% (49/50) 90.1% (10/11) 95.6% (259/271) 98.9% (276/279) 80.3% (49/61) 76.9% (10/13) 99.6% (259/260) 99.6% (276/277) Resolved ß TMA-TV 98.6% (69/70) 99.1% (536/541) 93.2% (69/74) 99.8% (536/537) Female Male 98.2% (56/57) 100% (13/13) 98.1% (259/264) 100% (277/277) 91.8% (56/61) 100% (13/13) 99.6% (259/260) 100% (277/277) α Sensitivity and specificity of TMA-TV compared to BTUB FRET PCR ß Sensitivity and specificity where infection status is determined by two positive amplified results from TMA-TV, BTUB FRET PCR or alternate PCR using primer set TVK3 and TVK4 or wet preparation result Table 2. Additional testing of Male discordant samples 3 Male discordant samples: all initially TMA-TV Pos / BTUB FRET PCR Neg Repeat TMA-TV Repeat BTUB Primers TVK 3/4 True Pos / Neg 1. + True pos 2. NA + True pos 3. NA + + True pos 1 Male Discordant sample: initially TMA-TV Neg / BTUB Pos 1. + - True neg 13

Table 3. Additional testing of female discordant samples for 12 Female Discordant samples: all initially TMA-TV Pos / BTUB Neg (QNS = quantity not sufficient) Repeat TMA Rpt. BTUB TVK 3/4 Wet Prep. Results True Pos or Neg 1. + - + + True pos 2. + - + - True pos 3. + - + - True pos 4. + + + - True pos 5. Not done + + + True pos 6. Not done - + Not done True pos 7. Not done - + + True pos 8. + - - - True neg 9. + - - - True neg 10. - - Not done - True neg 11. - - Not done - True neg 12. + QNS QNS - True neg Additional testing of female discordant samples 1 Female Discordant sample: initially TMA-TV Neg / BTUB Pos 1. - + + - True pos 14